Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
With @WeForest, UCB will ensure that about 12 000 hectares of degraded woodland in Ethiopia’s Tigray will be restored resulting in the sequestration of nearly 200 000 tons of CO2 by 2030 #UCB90 #Environment https://t.co/K50xSffHFY https://t.co/9pUR9Dhgt7
— UCB News (@ucb_news) 17.12.2018 -
Thank you! it was great to celebrate surrounded by so many esteemed guests. @DBoBruessel #UCB90 https://t.co/hFODtTvoty
— UCB News (@ucb_news) 14.12.2018 -
Guest were duly impressed by the wearable technology on display. Thank you for the great partnership @byteflies #UCB90 https://t.co/raZgPanki0
— UCB News (@ucb_news) 14.12.2018
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
